about
Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancerAn integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progressionThe role of SPINK1 in ETS rearrangement-negative prostate cancersGolgi protein GOLM1 is a tissue and urine biomarker of prostate cancerAGTR1 overexpression defines a subset of breast cancer and confers sensitivity to losartan, an AGTR1 antagonistMetabolomic profiles delineate potential role for sarcosine in prostate cancer progressionalpha-Methylacyl-CoA racemase: expression levels of this novel cancer biomarker depend on tumor differentiationADAM15 disintegrin is associated with aggressive prostate and breast cancer diseaseRecurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer.Role of the TMPRSS2-ERG gene fusion in prostate cancerAutoantibody signatures in prostate cancer.Autoantibody profiles reveal ubiquilin 1 as a humoral immune response target in lung adenocarcinoma.RHAMM (CD168) is overexpressed at the protein level and may constitute an immunogenic antigen in advanced prostate cancer disease.Proteomic interrogation of androgen action in prostate cancer cells reveals roles of aminoacyl tRNA synthetasesAn integrative approach to reveal driver gene fusions from paired-end sequencing data in cancer.Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanomaAntibody-based detection of ERG rearrangement-positive prostate cancerTRIP13 promotes error-prone nonhomologous end joining and induces chemoresistance in head and neck cancerChanges in differential gene expression because of warm ischemia time of radical prostatectomy specimens.The miR-124-prolyl hydroxylase P4HA1-MMP1 axis plays a critical role in prostate cancer progression.Characterization of TMPRSS2:ETV5 and SLC45A3:ETV5 gene fusions in prostate cancer.Induced chromosomal proximity and gene fusions in prostate cancer.Defining aggressive prostate cancer using a 12-gene model.The tumor suppressor gene rap1GAP is silenced by miR-101-mediated EZH2 overexpression in invasive squamous cell carcinomaTMPRSS2-ERG-mediated feed-forward regulation of wild-type ERG in human prostate cancers.Coordinated regulation of polycomb group complexes through microRNAs in cancer.Selection and cloning of poly(rC)-binding protein 2 and Raf kinase inhibitor protein RNA activators of 2',5'-oligoadenylate synthetase from prostate cancer cellsCharacterization of KRAS rearrangements in metastatic prostate cancer.The kinase activity of the Ser/Thr kinase BUB1 promotes TGF-β signaling.Inhibition of histone methylation arrests ongoing graft-versus-host disease in mice by selectively inducing apoptosis of alloreactive effector T cells.Amplified centrosomes may underlie aggressive disease course in pancreatic ductal adenocarcinoma.Tumor cell-selective regulation of NOXA by c-MYC in response to proteasome inhibition.Role of transcriptional corepressor CtBP1 in prostate cancer progressionCancer mediates effector T cell dysfunction by targeting microRNAs and EZH2 via glycolysis restriction.Role and regulation of coordinately expressed de novo purine biosynthetic enzymes PPAT and PAICS in lung cancer.A systems approach to model metastatic progression.Inhibition of CCN6 (Wnt-1-induced signaling protein 3) down-regulates E-cadherin in the breast epithelium through induction of snail and ZEB1.Differential proteomic alterations between localised and metastatic prostate cancer.Genomic and Epigenomic Alterations in CancerGenomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer.
P50
Q24302687-3772C607-E19D-4691-AC6A-B12A46911AFFQ24313269-DD46AA4F-DA0A-486A-AE24-A52ADD669BADQ24647020-36AD7F7E-C806-44E1-9486-E6F0BA233EDCQ24649955-5143BAD0-BA5E-41B5-AF9A-E2F3762F4020Q24652842-5299FAE3-845D-400B-A26D-F55138C3E55AQ24654019-68A90E83-CA26-403B-8B5B-5EEB257DF8AEQ24669748-F16A1027-67A9-4F7F-A555-81D995A45B5DQ24676359-044E2DA7-105E-4388-B9F3-FAB43C116A36Q27824849-0C69C4E8-41CC-4052-A39B-B903C716AF91Q28269156-E6CFC219-D022-46C3-98C6-2E12985F54EBQ33223730-D32E469C-4D99-4FE1-A509-9C05936975B7Q33281166-30193634-6869-4CE1-AA10-0FBD7E985306Q33499385-18991F40-AA99-449D-B20B-773B031BF5C8Q33504593-E0DDD010-7199-498E-A579-6F4ADACB9837Q33514281-19DC68CF-7ABC-405D-92C0-7B6489A2BA5DQ33992803-DC5DFCC0-29DE-48C6-B16D-B7F2834AD405Q34009867-F52BDC07-4AD0-4C05-8C02-34491E7DB25AQ34034240-AD7431B4-E16D-43CC-AB18-754C48E61F27Q34157522-F5BAF52C-08A2-40A4-AAC6-6D650D76AAE8Q34334347-024D066C-1BFC-4D2C-9A95-502AB4CAAC5FQ34732738-650E207D-0609-459F-B324-957DD1123C4AQ35014197-780639E8-74AC-43D4-B719-95DA9AB4BB50Q35060298-6F3047D9-D123-4867-BC9C-227DB47757C2Q35159486-B3B1375F-D2C0-4833-A803-502F1BDF4E4EQ35165354-7E216109-63AE-471A-B881-AFC99B2DBA00Q35167450-99D068B5-824A-46D8-82D1-D86436A3A9E2Q35545869-EBEF5D37-6792-4FDF-A51E-DCC1E82B5609Q35581673-2ADFB94E-9DEF-4613-B164-6C7A3456702CQ35633748-474EF1DE-A78F-4E34-AAEC-521C470E8890Q35917157-1E13EA31-FC99-4F67-A6FB-6DE808AB8A70Q36189152-01E1DF3C-40C8-4630-A154-2BB5FE2F40A2Q36288668-D6023660-A45E-425E-8C50-7EAA00AA0623Q36343763-FE6D474B-F304-420A-8020-FC895D9A01ECQ36386431-FCDC54BE-968F-4770-83F3-28A911777F24Q36414207-8598D9D9-5540-4909-A892-29D9466504D6Q36494858-1A489021-AC50-44E2-8AAE-26BA36EC1D64Q36512260-BB388B51-B289-416A-987F-67F59361FCA1Q36553042-21D17150-9A6E-46E2-A8A6-C5B6591A5593Q37057145-1385D48C-CB2D-402E-A2DA-B664C7344E2BQ37198891-08A4DF55-D877-4403-A323-6B63A5F8874B
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Sooryanarayana Varambally
@ast
Sooryanarayana Varambally
@en
Sooryanarayana Varambally
@es
Sooryanarayana Varambally
@nl
Sooryanarayana Varambally
@sl
type
label
Sooryanarayana Varambally
@ast
Sooryanarayana Varambally
@en
Sooryanarayana Varambally
@es
Sooryanarayana Varambally
@nl
Sooryanarayana Varambally
@sl
prefLabel
Sooryanarayana Varambally
@ast
Sooryanarayana Varambally
@en
Sooryanarayana Varambally
@es
Sooryanarayana Varambally
@nl
Sooryanarayana Varambally
@sl
P106
P1153
35425161700
P31
P496
0000-0002-2277-1127